Response to "An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation".

George, Jamie; Farhat, Nada; Thomas, Emily

George, Jamie; Farhat, Nada; Thomas, Emily.

George J; Henry Ford Macomb Hematology/Oncology, Clinton Township, MI, USA.
Farhat N; Henry Ford Medical Center-Livonia, Livonia, MI, USA.
Thomas E; Henry Ford Health System, Detroit, MI, USA.

Am J Health Syst Pharm ; 79(22): 1979-1980, 2022 11 07.

Article in English | MEDLINE | ID: covidwho-1992110

Subject(s)

Glucagon-Like Peptide-1 Receptor; Insulin; Humans; Glucagon-Like Peptide-1 Receptor/agonists; Glucagon-Like Peptide 1; Glucagon

Keywords

GLP-1 agonist; diabetes; insulin; medication taper

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Glucagon-Like Peptide-1 Receptor / Insulin Limits: Humans Language: English Journal: Am J Health Syst Pharm Journal subject: Pharmacy / Hospitals Year: 2022 Document Type: Article Affiliation country: Ajhp

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google